Global, regional, and national burden of stroke, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
Carregando...
Citações na Scopus
1876
Tipo de produção
article
Data de publicação
2019
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE INC
Autores
JOHNSON, Catherine Owens
Minh Nguyen
ROTH, Gregory A.
NICHOLS, Emma
ALAM, Tahiya
ABATE, Degu
ABD-ALLAH, Foad
ABDELALIM, Ahmed
ABRAHA, Haftom Niguse
ABU-RMEILEH, Niveen Me
Citação
LANCET NEUROLOGY, v.18, n.5, p.439-458, 2019
Resumo
Background Stroke is a leading cause of mortality and disability worldwide and the economic costs of treatment and post-stroke care are substantial. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) provides a systematic, comparable method of quantifying health loss by disease, age, sex, year, and location to provide information to health systems and policy makers on more than 300 causes of disease and injury, including stroke. The results presented here are the estimates of burden due to overall stroke and ischaemic and haemorrhagic stroke from GBD 2016. Methods We report estimates and corresponding uncertainty intervals (UIs), from 1990 to 2016, for incidence, prevalence, deaths, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life-years (DALYs). DALYs were generated by summing YLLs and YLDs. Cause-specific mortality was estimated using an ensemble modelling process with vital registration and verbal autopsy data as inputs. Non-fatal estimates were generated using Bayesian meta-regression incorporating data from registries, scientific literature, administrative records, and surveys. The Socio-demographic Index (SDI), a summary indicator generated using educational attainment, lagged distributed income, and total fertility rate, was used to group countries into quintiles. Findings In 2016, there were 5.5 million (95% UI 5.3 to 5.7) deaths and 116.4 million (111.4 to 121.4) DALYs due to stroke. The global age-standardised mortality rate decreased by 36.2% (-39.3 to -33.6) from 1990 to 2016, with decreases in all SDI quintiles. Over the same period, the global age-standardised DALY rate declined by 34.2% (-37.2 to -31.5), also with decreases in all SDI quintiles. There were 13.7 million (12.7 to 14.7) new stroke cases in 2016. Global age-standardised incidence declined by 8.1% (-10.7 to -5.5) from 1990 to 2016 and decreased in all SDI quintiles except the middle SDI group. There were 80.1 million (74.1 to 86.3) prevalent cases of stroke globally in 2016; 41.1 million (38.0 to 44.3) in women and 39.0 million (36.1 to 42.1) in men. Interpretation Although age-standardised mortality rates have decreased sharply from 1990 to 2016, the decrease in age-standardised incidence has been less steep, indicating that the burden of stroke is likely to remain high. Planned updates to future GBD iterations include generating separate estimates for subarachnoid haemorrhage and intracerebral haemorrhage, generating estimates of transient ischaemic attack, and including atrial fibrillation as a risk factor.
Palavras-chave
Referências
- AHO K, 1980, B WORLD HEALTH ORGAN, V58, P113
- Arnao V, 2016, INT J STROKE, V11, P287, DOI 10.1177/1747493016632245
- Brainin M, 2018, INT J STROKE, V13, P633, DOI 10.1177/1747493018761190
- Coull AJ, 2004, BMJ-BRIT MED J, V328, P326, DOI 10.1136/bmj.37991.635266.44
- Emberson J, 2004, EUR HEART J, V25, P484, DOI 10.1016/j.ehj.2003.11.012
- Feigin V, 2018, STROKE, V49, P2248, DOI 10.1161/STROKEAHA.118.022161
- Feigin VL, 2017, LANCET NEUROL, V16, P877, DOI 10.1016/S1474-4422(17)30299-5
- Feigin VL, 2016, NAT REV NEUROL, V12, P501, DOI 10.1038/nrneurol.2016.107
- Feigin VL, 2009, LANCET NEUROL, V8, P355, DOI 10.1016/S1474-4422(09)70025-0
- Gaciong Z, 2013, CURR HYPERTENS REP, V15, P559, DOI 10.1007/s11906-013-0401-0
- Gakidou E, 2017, LANCET, V390, P1345, DOI 10.1016/S0140-6736(17)32366-8
- Gaziano TA, 2006, LANCET, V368, P679, DOI 10.1016/S0140-6736(06)69252-0
- Hart RG, 2007, ANN INTERN MED, V146, P857, DOI 10.7326/0003-4819-146-12-200706190-00007
- Heller DJ, 2017, CIRCULATION, V136, P1087, DOI 10.1161/CIRCULATIONAHA.117.027067
- Huisman MV, 2014, AM HEART J, V167, P329, DOI 10.1016/j.ahj.2013.12.006
- Jensen ET, 2015, ANN EPIDEMIOL, V25, P519, DOI 10.1016/j.annepidem.2015.03.008
- Jorgensen T, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3617
- Kottke TE, 2012, PREV CHRONIC DIS, V9, DOI 10.5888/pcd9.120009
- Krishnamurthi R, 2018, FIN PROGR INT STROK, P85
- Krishnamurthi R, 2019, STROKE, V50, P196, DOI 10.1161/STROKEAHA.118.023058
- Krogsboll LT, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e7191
- Naghavi M, 2017, LANCET, V390, P1151, DOI 10.1016/S0140-6736(17)32152-9
- O'Donnell MJ, 2016, LANCET, V388, P761, DOI 10.1016/S0140-6736(16)30506-2
- Owolabi M, 2018, J STROKE MED, V1, P65
- Powers WJ, 2018, STROKE, V49, pE46, DOI 10.1161/STR.0000000000000158
- Psaty BM, 2016, CIRCULATION, V133, P156, DOI 10.1161/CIRCULATIONAHA.115.018610
- Rajsic S, 2019, EUR J HEALTH ECON, V20, P107, DOI 10.1007/s10198-018-0984-0
- Smith WS, 2016, STROKE, V47, pE23, DOI 10.1161/STROKEAHA.115.010863
- Stevens GA, 2016, LANCET, V388, pE19, DOI 10.1016/S0140-6736(16)30388-9
- Thrift AG, 2017, INT J STROKE, V12, P13, DOI 10.1177/1747493016676285
- Venketasubramanian N, 2017, J STROKE, V19, P286, DOI 10.5853/jos.2017.00234
- Vos T, 2017, LANCET, V390, P1211, DOI 10.1016/S0140-6736(17)32154-2
- Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092388
- World Health Organization, GLOB ACT PLAN PREV C
- Yan LL, 2017, CARDIOVASCULAR RESP